Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Virus or component thereof
Patent
1995-05-03
1998-07-14
Achutamurthy, Ponnathapura
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Virus or component thereof
536 2372, 4353201, A61K 3921, C07H 2104, C12N 1500
Patent
active
057800383
ABSTRACT:
Polypeptides which include at least one antigenic and/or immunogenic determinant of the envelope protein (env) of the HIV-2 virus and their production by recombinant DNA technology and the DNA sequences, expression vectors and transformed single-cell organisms used in this process are provided. A method for the detection of HIV antibodies or HIV viruses in human sera or in other biological fluids is also provided.
REFERENCES:
patent: 4569794 (1986-02-01), Smith et al.
patent: 4812556 (1989-03-01), Vahine et al.
patent: 4925784 (1990-05-01), Crowl et al.
patent: 5283320 (1994-02-01), Vahlne et al.
Clavel, et al., Science 233:343-346 (1986) "Isolation of a New Human Retrovirus from West African Patients with AIDS".
Clavel, et al., Nature 324:691-69 (1986) "Molecular Cloning and Polymorphism of the Human Immune Deficiency Virus Type 2".
Guyader, et al., Nature 326:662-669 (1987) "Genome Organization and Transactivation of the Human Immunodeficiency Virus Type 2".
Brun-Vezinet, et al., Lancet 1:128-132 (1987) "Lymphadenopathy-Asso. Virus Type 2 in AIDS and AIDS-related complex".
Hochuli, et al., Biol. Chem. Hoppe-Seyler 368:748 (1987) "Alpha-alkyl Nitrilotriacetic Acid Adsorbants . . .".
Villarejo, et al., J. Bacteriol. 120:466-474 (1974) "Beta Galactosidase from Termination and Deletion Mutant Strains".
Certa, et al., EMBO J.5(11):3051-3056 (1986) "Subregions of a Conserved Part of the HIV . . .".
Shoeman, et al., Anal. Biochem. 161:370-379 (1987) "Comparison of Recombinant Human Immunodeficiency . . .".
Kyte and Doolittle, J. Mol. Biol. 157:105-132 (1982) "A Simple Method for Displaying the Hydropathic Character of a Protein".
Pauletti, et al., Anal. Biochem. 151:540-546 (1985) "Application of a Modified Computer Algorithm in Determining Potential Antigenic Determinants Asso. with the . . .".
Hopp and Woods, Proc. Natl. Acid. Sci. 78(6):3824-3828 (1981) "Prediction of Protein Antigenic Determinants from Amino Acid Sequences".
Cordonnier, et al., Nature 340:571-574 (1989) "Single Amino Acid Changes in HIV . . .".
Ponger, Methods in Enzym. 154:450-473 (1987) "The Use of Structural Profiles. . .".
Norrby E, Biberfield G, Chiodi F, von Gegerfeldt A, Naucler A, Parks E, Lerner R. Discrimination between antibodies to HIV and to related retroviruses using site directed serology; Nature 329, 2248-250, Sep. 17, 198.
Guyader M,Emerman M, Sonigo P,Clavel F, Montagnier L,Alizon M; Genome organization and transactivation of the HIV-2; Nature 326:662-669, Apr. 16, 198.
Shoeman R,Young D, Pottathil R, Victor J,Conroy R,Crowl R,Coleman T,Heimer E,Lai C,Ganguly K,Reddy E,Skalka A, Khan F,Weissbach H;Comparison of recombinant HIV gag precursor ad gag/env fusion proteins and a synthetic env peptide as diagnostic reagents; An, 1987.
Certa U,Bannwarth W,Stuber D,Gentz R,Lanzer M,Le Grice S,Guillot F,Wendler I,Hunsmann G,Bujard H,Mous J; Subregions of a conserved part of the HIV gp41 transmembrane protein are differently recognized by antibodies of infected individuals; EMBO 5(11):3, 1986.
Gann J,McCormick J,Mitchell S,Nelson J, Oldstone M; Synthetic peptide immunoassay distinguishes HIV type1 and HIV type2 infections; Science 237:1346-1349, Sep. 11, 198.
Minassian A,Kalyanaranman V,Gallo R,Popoviv M; Monoclonal antibodies against HIV type2 core proteins:Cross-reactivity with type1 and SIV: PNAS 85:6939-6943, Sep. 1988.
Putney S,MatthewsT,Robey G,Lynn D, Robert-Guroff M, Mueller W, Langlois A,Ghrayeb J,Petteway S,Weinhold K,Fischinger P,Wong-Staal F,Gallo R, Bolognesi D;HTLV-III/LAV-neutralizing antibodies to an E.coli-produced fragment of the virus envelope; Science 234, Dec. 12, 1919.
Clavel F. et al., Human immunodeficiency virus type 2 infection associated with AIDS in West Africa, New England Journal of Medicine, 316(19):1180-1185, May 1987.
Gnann J. et al. Synthetic peptide immunoassay distinguishes HIV type 1 and HIV type 2 infections, Science 237:1346-1349, Sep. 1987.
Guyader M., Genome organization and transactivation of the human immunodeficiency virus type 2, Nature 326:662-669, Apr. 1987.
Bannwarth Wilhelm
Caspers Patrick
Le Grice Stuart
Mous Jan
Achutamurthy Ponnathapura
Johnston George W.
Park Hankyel T.
Rocha-Tramaloni Patricia S.
Roche Diagnostic Systems, Inc.
LandOfFree
HIV-2 envelope polypeptides does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with HIV-2 envelope polypeptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and HIV-2 envelope polypeptides will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1879274